San Diego Business Journal

Biotech Financing

BIOTECH: Halozyme Gets Creative in Pursuit of Cash By Brittany Meiling Originally published July 7, 2016 at 11:40 a.m., updated July 7, 2016 at 11:40 a.m.
   
Research scientist Li Zhu works in the lab at Halozyme Inc., which is developing drugs that target cancer.

Research scientist Li Zhu works in the lab at Halozyme Inc., which is developing drugs that target cancer. Photo by Melissa Jacobs.

— In today’s market, with valuations down and investors wary, it’s critical for biotechs to get creative when looking for cash to fuel research...

Prev

Page 1 of 2.

Take 1 minute to subscribe and you’ll get this story immediately, plus:

Already a subscriber? Sign in

  • 51 weekly issues: $153 value
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives: $150 value
  • Book of Lists — the biggest, hottest companies in San Diego: $75 value
  • NEW: San Diego 500 — influential business leaders you need to know: $50 value
  • Total Package Value: $428

Yours for only $129